Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose–exposed endothelial cells
暂无分享,去创建一个
[1] B. S. Sekhon,et al. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases. , 2015, Mini reviews in medicinal chemistry.
[2] S. Yamagishi,et al. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression , 2014, Cardiovascular Diabetology.
[3] R. Kawamori,et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy , 2012, Diabetic medicine : a journal of the British Diabetic Association.
[4] K. Martin,et al. Aldose Reductase, Oxidative Stress, and Diabetic Mellitus , 2012, Front. Pharmacol..
[5] Ravichandran Ramasamy,et al. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. , 2010, Circulation research.
[6] P. Bennett,et al. Quantitative determination of endogenous sorbitol and fructose in human nerve tissues by atmospheric-pressure chemical ionization liquid chromatography/tandem mass spectrometry. , 2005, Rapid communications in mass spectrometry : RCM.
[7] T. Imaizumi,et al. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.
[8] T. Jomori,et al. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. , 2002, Biochemical and biophysical research communications.
[9] M. Itoh,et al. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. , 2002, Journal of diabetes and its complications.
[10] K. Kuboki,et al. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. , 2001, Journal of diabetes and its complications.
[11] K. Yoshida,et al. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase. , 2001, Biochemistry.
[12] T. Wakatsuki,et al. Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. , 2001, Life sciences.